Cargando…
COVID-19 vaccines: neutralizing antibodies and the alum advantage
Achieving high levels of neutralizing antibodies to the spike protein of SARS-CoV-2 in a safe manner is likely to be crucial for an effective vaccine. Here, we propose that aluminium-based adjuvants might hold the key to this.
Autores principales: | Hotez, Peter J., Corry, David B., Strych, Ulrich, Bottazzi, Maria Elena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7271131/ https://www.ncbi.nlm.nih.gov/pubmed/32499636 http://dx.doi.org/10.1038/s41577-020-0358-6 |
Ejemplares similares
-
COVID-19 vaccine design: the Janus face of immune enhancement
por: Hotez, Peter J., et al.
Publicado: (2020) -
Coronavirus vaccine-associated lung immunopathology-what is the significance?
por: Bottazzi, Maria Elena, et al.
Publicado: (2020) -
A Recombinant Protein XBB.1.5 RBD/Alum/CpG Vaccine Elicits High Neutralizing Antibody Titers against Omicron Subvariants of SARS-CoV-2
por: Thimmiraju, Syamala Rani, et al.
Publicado: (2023) -
The SARS-CoV-2 Vaccine Pipeline: an Overview
por: Chen, Wen-Hsiang, et al.
Publicado: (2020) -
The potential role of Th17 immune responses in coronavirus immunopathology and vaccine-induced immune enhancement
por: Hotez, Peter J., et al.
Publicado: (2020)